Barclays Maintains Overweight on Charles River, Raises Price Target to $330

9/25/2026
Impact: 70
Healthcare

Barclays analyst Luke Sergott has maintained an Overweight rating on Charles River (NYSE: CRL) and increased the price target from $300 to $330. This adjustment reflects a positive outlook on the company's performance.

AI summary, not financial advice

Share: